Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

The FY22 call - CTAD rolling disaster revealed Anavex for what it is: A third-rate biotech company run by a third-rate autocratic CEO with little to show for it. If your drug candidate is actually safe and effective, you don’t have to move the goal posts, deflect attention with shiny new objects, pretend your trials are something they are not, and cherry pick the data.

For years, Missling had the good fortune of having a retail shareholder base that did not have the capacity to question what he said and instead worshipped him like a god. Now that he’s got the attention of people who actually know their stuff, he can no longer get away with the obfuscation and spin. In my opinion, and in the opinion of institutional biotech investors (based on the fact that not a single one of them owns the stock), it’s pretty much ballgame over.

The company will keep the light on because of all the cash on hand but the chances for ever getting an approval are less than 1%.